Global Allopurinol Tablets Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Capsules, Tablets, and Others), By Dose (100mg, 300mg, and Others), By Indications (Kidney Stones, Gout, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Allopurinol Tablets Market Insights Forecasts to 2033

• The Global Allopurinol Tablets Market Size was estimated at USD 1.01 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 6.63% from 2023 to 2033
• The Worldwide Allopurinol Tablets Market Size is expected to reach USD 1.92 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Allopurinol Tablets Market Size is anticipated to exceed USD 1.92 Billion by 2033, growing at a CAGR of 6.63% from 2023 to 2033.

Market Overview

The allopurinol tablets market is a sector of the pharmaceutical industry that deals with the development, formulation, and commercialization of the allopurinol tablets used in the management of gout disease, and hyperuricemia. Allopurinol is a xanthine oxidase inhibitor that prevents the conversion of hypoxanthine and xanthine to uric acid, a substance commonly used to treat hyperuricemia, high uric acid levels, cancer medicines, kidney stones, and gout. It works by decreasing the body's production of uric acid, which can lead to joint pain and inflammation. It is also used to prevent or lower excess uric acid levels, which can lead to gout or gouty arthritis. The marketed products of the allopurinol are the Zyloprim, Zylowell, AllopurCare, Apllinol, etc. The rising prevalence of gout escalates the need for gout therapeutics like allopurinol tablets for the treatment of gout by lowering the uric acid level resulting in market growth. For instance, the data published in the Journal, the Lancet Rheumatology states that gout is an inflammatory arthritis causing severe joint pain and swelling, which can progress to chronic tophaceous or erosive gout. In 2020, it was 3 times higher in males than in females and increased with age. The prevalence is estimated to reach 95.8 million by 2050, with population growth being the largest contributor. The age-standardized gout prevalence is 667 per 100,000 population. The global age-standardized years lived with disability (YLD) rate of gout was 20.5 per 100,000 population in 2020. High BMI accounts for 34% of YLDs due to gout, and kidney dysfunction accounts for 11%.

Report Coverage

This research report categorizes the global allopurinol tablets market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global allopurinol tablets market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global allopurinol tablets market.

Driving Factors:

Increasing the prevalence of the gout:

The most prevalent inflammatory arthritis in adults is gout, which is three to four times more prevalent than rheumatoid arthritis. It is particularly common in racial/ethnic minorities and rises with age; globally, its prevalence ranges from 1 to 4%. Males are more likely to have gout, which rises with age and reaches 11–13% and 0.4% in those over 80. Dietary variables, concomitant diseases, and obesity are risk factors. Erectile dysfunction, atrial fibrillation, obstructive sleep apnea, osteoporosis, and venous thromboembolism are among the comorbidities that gout raises the risk of, in addition to cardiovascular disease and chronic renal disease.

Innovations in the allopurinol formulations:

The increasing focus on novel drug delivery systems such as liposomes, niosomes, etc., drives the market growth. For instance, allopurinol-loaded chitosan-coated magnetic nanoparticles (A-MNPs) have shown promise in the treatment of hyperuricemic kidney stones. A hydrophilic chitosan polymer coats these nanoparticles to stop the immune system from eliminating particles. Studies conducted in vivo demonstrate enhanced availability and extended medication release. Researchers are looking into combining allopurinol with other urate-lowering treatments to increase effectiveness and lessen side effects; this is especially advantageous for individuals with refractory gout.

Restraining Factors

The availability of alternative medications for the management of gout, rigorous government guidelines, side effects associated with allopurinol usage such as skin rash, headache, and nausea, and limited awareness of the gout disease and the treatment medications may impede the market growth.

Market Segmentation

The global allopurinol tablets market share is classified into dosage form, dose, indications, and distribution channel.

• The tablets segment dominated the market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global allopurinol tablets market is categorized into capsules, tablets, and others. Among these, the tablets segment dominated the market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to the greater chemical and physical stability, accurate dosing, patient compliance, ease of administration, and availability in the novel drug delivery system such as controlled drug delivery tablets, available in various doses as per the age of the individual and type of population, better disintegration time, faster onset of action, longer shelf, and reduced risk of the microbial contamination due to the absence of water in the tablet formulation.

• The 100mg segment accounted for a significant share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the dose, the global allopurinol tablets market is categorized into 100mg, 300mg, and others. Among these, the 100mg segment accounted for a significant share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is owing to allopurinol 100 mg tablets being the first-line treatment for gout patients, minimized risk of the side effects, and convenient to all adult and geriatric populations.

• The gout segment held the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global allopurinol tablets market is categorized into kidney stones, gout, and others. Among these, the gout segment held the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is ascribed to the increasing prevalence of gout, increasing intake of purine-rich food, consuming more diuretics leads to gout, allopurinol is the first-line treatment for gout, effective and safe, decreases the uric acid level, and prevents the progression of gout.

• The hospital pharmacies segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global allopurinol tablets market is categorized into retail pharmacies, online pharmacies, hospital pharmacies, and others. Among these, the hospital pharmacies segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The sector growth is attributed to the availability of a wide stock of allopurinol tablets, cost-effectiveness medications, compounding, and dispensing facilities, monitoring the blood profiles, collaborations of the hospital pharmacies and hospitals leading to better healthcare outcomes for the patients, and personalized medications.

Regional Segment Analysis of the Global Allopurinol Tablets Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global allopurinol tablets market over the predicted timeframe.

North America is anticipated to hold the largest share of the global allopurinol tablets market over the predicted timeframe. The high incidence of kidney stones and gout, the established healthcare system, and the emphasis on managing chronic diseases are all contributing factors to the growth of the US market for hyperuricemia drugs. As evidence-based treatment options are adopted by healthcare professionals in North America, the expansion has been facilitated by significant vendors and ongoing research activities. The research and distribution of drugs like allopurinol are aided by rising healthcare spending in the US, and favorable laws and regulations make it easier for these drugs to be approved and to become commercial.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. Allopurinol's market in Asia Pacific is growing as a result of increased healthcare awareness, better infrastructure, and a significant patient base. Urbanization, shifting lifestyles, and government programs are all contributing to China's and India's rapid growth. The market is expanding as a result of patients having access to affordable generic versions of allopurinol, which are necessary drugs for treating kidney stones and gout. The prevalence of diseases needing allopurinol therapy rises in Asia Pacific nations owing to an aging population.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global allopurinol tablets market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Zydus Cadila
• Mylan N. V.
• Jubilant Generics Limited
• Apotex Inc.
• GlaxoSmithKline
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Lupin Limited
• Amneal Pharmaceuticals LLC
• Cipla Limited
• Hetero Drugs Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2024, Camber Pharmaceuticals announced the introduction of the Allopurinol Tablets to its product portfolio. Allopurinol is used in the management of the signs and symptoms of primary and secondary gout and acts as an Anti-Hyperuricemic medication.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global allopurinol tablets market based on the below-mentioned segments:

Global Allopurinol Tablets Market, By Dosage Form

• Capsules
• Tablets
• Others

Global Allopurinol Tablets Market, By Dose

• 100mg
• 300mg
• Others

Global Allopurinol Tablets Market, By Indications

• Kidney Stones
• Gout
• Others

Global Allopurinol Tablets Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Others

Global Allopurinol Tablets Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa